HypertensionPhase 4NCT00140959
Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)
A Phase 4 study testing MK0954, losartan potassium/Duration of Treatment: 18 weeks and Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks in people with Hypertension, run by Organon and Co.
Trial summary
A study to evaluate the effects of combination losartan versus combination atenolol in patients with ambulatory systolic hypertension. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Hypertension
- What is being tested?
- MK0954, losartan potassium/Duration of Treatment: 18 weeks and Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- 1 Feb 2003to 30 Jun 2004
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Males or females at least 18 years of age who have ambulatory systolic hypertension.
Who cannot join
None listed.
About this study
Official title: Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.
A study to evaluate the effects of combination losartan versus combination atenolol in patients with ambulatory systolic hypertension.
- Conditions
- Hypertension
- Being tested
- MK0954, losartan potassium/Duration of Treatment: 18 weeks, Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MK0954, losartan potassium/Duration of Treatment: 18 weeksDrug
Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeksDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean daytime ambulatory systolic blood pressure
Secondary outcomes (4)
Ambulatory BP
Pulse pressure
Trough sitting BP
Percentage of patients who reach goal ambulatory systolic BP
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2005 (estimated)
- Study start1 Feb 2003
- Primary completion30 Jun 2004
- Study completion30 Jun 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants
Sponsor and investigators
- Lead sponsor
- Organon and Co
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Monitor, Study director, Merck Sharp & Dohme LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00140959
- Sponsor's protocol ID
- 0954A-309
- Other IDs
- 2005_061
- Status last verified
- Feb 2022
- First submitted
- 31 Aug 2005
- Last updated
- 15 Aug 2024
- Results posted
- No
Publications
Lacourciere Y, Poirier L, Lefebvre J. Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension. Can J Cardiol. 2007 Apr;23(5):377-82. doi: 10.1016/s0828-282x(07)70771-7.
PubMed 17440643
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.
- ClinicalTrials.gov ID
- NCT00140959
- Acronym / sponsor ID
- 0954A-309
- Conditions
- Hypertension
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants
- Lead sponsor
- Organon and CoIndustry (pharma, biotech, devices)
- Study start
- 1 Feb 2003 (actual)
- Primary completion
- 30 Jun 2004 (actual)
- Study completion
- 30 Jun 2004 (actual)
- First posted
- 1 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study to evaluate the effects of combination losartan versus combination atenolol in patients with ambulatory systolic hypertension.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Males or females at least 18 years of age who have ambulatory systolic hypertension.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MK0954, losartan potassium/Duration of Treatment: 18 weeks | Drug | – |
| Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks | Drug | – |
Primary outcome
Mean daytime ambulatory systolic blood pressure
4 secondary outcomes
Ambulatory BP
Pulse pressure
Trough sitting BP
Percentage of patients who reach goal ambulatory systolic BP
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2024.
- Background: PubMed 17440643Lacourciere Y, Poirier L, Lefebvre J. Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension. Can J Cardiol. 2007 Apr;23(5):377-82. doi: 10.1016/s0828-282x(07)70771-7.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Monitor study director
Merck Sharp & Dohme LLC
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing MK0954, losartan potassium/Duration of Treatment: 18 weeks and Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks in people with Hypertension, run by Organon and Co.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean daytime ambulatory systolic blood pressure. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00140959, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2024.